Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), STAT1 inhibitors(Signal transducer and activator of transcription 1-alpha/beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Australia (14 Oct 2026), |
Regulation- |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Acute Graft Versus Host Disease | Australia | 14 Oct 2026 | |
| Chronic graft-versus-host disease | Australia | 14 Oct 2026 | |
| Polycythemia Vera | Australia | 14 Oct 2026 | |
| Post-essential thrombocythemia myelofibrosis | Australia | 14 Oct 2026 | |
| Post-polycythemia vera myelofibrosis | Australia | 14 Oct 2026 | |
| Primary Myelofibrosis | Australia | 14 Oct 2026 | |
| Splenomegaly | Australia | 14 Oct 2026 |





